Sofosbuvir and velpatasvir with or without voxilaprevir in direct-acting antiviral-naïve chronic hepatitis C: patient-reported outcomes from POLARIS 2 and 3
Author:
Affiliation:
1. Falls Church; VA USA
2. Washington DC USA
3. New York NY USA
4. Clichy France
5. Auckland New Zealand
6. San Antonio TX USA
7. London UK
8. Victoria Australia
9. Montréal Québec Canada
10. Frankfurt am Main Germany
11. Atlanta GA USA
Funder
Gilead Sciences
Publisher
Wiley
Subject
Pharmacology (medical),Gastroenterology,Hepatology
Link
http://onlinelibrary.wiley.com/wol1/doi/10.1111/apt.14423/fullpdf
Reference46 articles.
1. Efficacy of 8 weeks of sofosbuvir, velpatasvir, and voxilaprevir in patients with chronic HCV infection: 2 phase 3 randomized trials;Jacobson;Gastroenterology,2017
2. Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection;Feld;N Engl J Med,2015
3. ION-1 Investigators. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection;Afdhal;N Engl J Med,2014
4. VALENCE Investigators. Sofosbuvir and ribavirin in HCV genotypes 2 and 3;Zeuzem;N Engl J Med,2014
5. ION-3 Investigators. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis;Kowdley;N Engl J Med,2014
Cited by 42 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Virtual screening indicates potential inhibitors of the P2X7 receptor;Computers in Biology and Medicine;2023-09
2. Sofosbuvir/Velpatasvir/Voxilaprevir Experience in Treatment-Naive Chronic Hepatitis C Patients: Preliminary Findings of Real World Data;Viral Hepatitis Journal;2023-08-01
3. Patients with severe mental illness and hepatitis C virus infection benefit from new pangenotypic direct-acting antivirals: Results of a literature review;Gastroenterología y Hepatología;2023-05
4. Patients with severe mental illness and hepatitis C virus infection benefit from new pangenotypic direct-acting antivirals: Results of a literature review;Gastroenterología y Hepatología (English Edition);2023-05
5. Is fatigue related to the severity of liver inflammation in patients with chronic liver disease? A cross-sectional study;BMJ Open;2023-04
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3